

## 8. Literaturverzeichnis

1. Peat JK, Li J: **Reversing the trend: reducing the prevalence of asthma.** *J Allergy Clin Immunol* 1999, **103**:1-10.
2. Maggi E: **The TH1/TH2 paradigm in allergy.** *Immunotechnology* 1998, **3**:233-244.
3. Leung DY: **Molecular basis of allergic diseases.** *Mol Genet Metab* 1998, **63**:157-167.
4. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE: **The IL-4 receptor: signaling mechanisms and biologic functions.** *Annu Rev Immunol* 1999, **17**:701-738.
5. Mosmann TR, Sad S: **The expanding universe of T-cell subsets: Th1, Th2 and more.** *Immunol Today* 1996, **17**:138-146.
6. Romagnani S: **The Th1/Th2 paradigm.** *Immunol Today* 1997, **18**:263-266.
7. Romagnani S: **T-cell subsets (Th1 versus Th2).** *Ann Allergy Asthma Immunol* 2000, **85**:9-18; quiz 18, 21.
8. Scott P, Kaufmann SH: **The role of T-cell subsets and cytokines in the regulation of infection.** *Immunol Today* 1991, **12**:346-348.
9. Miossec P: **Acting on the cytokine balance to control auto-immunity and chronic inflammation.** *Eur Cytokine Netw* 1993, **4**:245-251.
10. Finkelman FD, Holmes J, Katona IM, Urban JF, Jr., Beckmann MP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE: **Lymphokine control of in vivo immunoglobulin isotype selection.** *Annu Rev Immunol* 1990, **8**:303-333.
11. Worm M, Henz BM: **Molecular regulation of human IgE synthesis.** *J Mol Med* 1997, **75**:440-447.
12. Bacharier LB, Jabara H, Geha RS: **Molecular mechanisms of immunoglobulin E regulation.** *Int Arch Allergy Immunol* 1998, **115**:257-269.
13. Naclerio RM, Baroody F: **Understanding the inflammatory processes in upper allergic airway disease and asthma.** *J Allergy Clin Immunol* 1998, **101**:S345-351.
14. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP: **IL-4 enhances proliferation and mediator release in mature human mast cells.** *Proc Natl Acad Sci U S A* 1999, **96**:8080-8085.
15. Redrup AC, Howard BP, MacGlashan DW, Jr., Kagey-Sobotka A, Lichtenstein LM, Schroeder JT: **Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures.** *J Immunol* 1998, **160**:1957-1964.
16. Bracke M, Dubois GR, Bolt K, Bruijnzeel PL, Vaerman JP, Lammers JW, Koenderman L: **Differential effects of the T helper cell type 2-derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils.** *J Immunol* 1997, **159**:1459-1465.

17. Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA: **IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo.** *J Immunol* 1999, **162**:6233-6237.
18. Cohn L, Homer RJ, MacLeod H, Mohrs M, Brombacher F, Bottomly K: **Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils.** *J Immunol* 1999, **162**:6178-6183.
19. Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B, Sugamura K, Wunderli-Allenspach H, Moser R: **Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain.** *Blood* 1996, **87**:4286-4295.
20. Mochizuki M, Bartels J, Mallet AI, Christophers E, Schroder JM: **IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy.** *J Immunol* 1998, **160**:60-68.
21. Chomarat P, Banchereau J: **Interleukin-4 and interleukin-13: their similarities and discrepancies.** *Int Rev Immunol* 1998, **17**:1-52.
22. Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, et al.: **Requirement for IL-13 independently of IL-4 in experimental asthma.** *Science* 1998, **282**:2261-2263.
23. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD: **Interleukin-13: central mediator of allergic asthma.** *Science* 1998, **282**:2258-2261.
24. Li L, Xia Y, Nguyen A, Lai YH, Feng L, Mosmann TR, Lo D: **Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells.** *J Immunol* 1999, **162**:2477-2487.
25. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: **Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.** *J Clin Invest* 1999, **103**:779-788.
26. Le HV, Ramanathan L, Labdon JE, Mays-Ichinco CA, Syto R, Arai N, Hoy P, Takebe Y, Nagabhushan TL, Trotta PP: **Isolation and characterization of multiple variants of recombinant human interleukin 4 expressed in mammalian cells.** *J Biol Chem* 1988, **263**:10817-10823.
27. Wlodaver A, Pavlovsky A, Gustchina A: **Crystal structure of human recombinant interleukin-4 at 2.25 Å resolution.** *FEBS Lett* 1992, **309**:59-64.
28. Walter MR, Cook WJ, Zhao BG, Cameron RP, Jr., Ealick SE, Walter RL, Jr., Reichert P, Nagabhushan TL, Trotta PP, Bugg CE: **Crystal structure of recombinant human interleukin-4.** *J Biol Chem* 1992, **267**:20371-20376.
29. Redfield C, Smith LJ, Boyd J, Lawrence GM, Edwards RG, Smith RA, Dobson CM: **Secondary structure and topology of human interleukin 4 in solution.** *Biochemistry* 1991, **30**:11029-11035.

30. Powers R, Garrett DS, March CJ, Frieden EA, Gronenborn AM, Clore GM: Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. *Science* 1992, **256**:1673-1677.
31. Müller T, Oehlenschläger F, Buehner M: Human interleukin-4 and variant R88Q: phasing X-ray diffraction data by molecular replacement using X-ray and nuclear magnetic resonance models. *J Mol Biol* 1995, **247**:360-372.
32. Presnell SR, Cohen FE: Topological distribution of four-alpha-helix bundles. *Proc Natl Acad Sci U S A* 1989, **86**:6592-6596.
33. Heldin CH: Dimerization of cell surface receptors in signal transduction. *Cell* 1995, **80**:213-223.
34. Nicola NA: Structural aspects of cytokine/receptor interactions. *Ann N Y Acad Sci* 1995, **766**:253-262.
35. Kruse N, Shen BJ, Arnold S, Tony HP, Muller T, Sebald W: Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. *Embo J* 1993, **12**:5121-5129.
36. Bazan JF: Structural design and molecular evolution of a cytokine receptor superfamily. *Proc Natl Acad Sci U S A* 1990, **87**:6934-6938.
37. Cosman D: The hematopoietin receptor superfamily. *Cytokine* 1993, **5**:95-106.
38. Hage T, Sebald W, Reinemer P: Crystal structure of the Interleukin-4/receptor α-chain complex reveals a mosaic binding interface. *Cell* 1999, **97**:271-281.
39. VanderKuur JA, Wang X, Zhang L, Campbell GS, Allevato G, Billestrup N, Norstedt G, Carter-Su C: Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase. *J Biol Chem* 1994, **269**:21709-21717.
40. Fukunaga R, Ishizaka-Ikeda E, Nagata S: Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. *Cell* 1993, **74**:1079-1087.
41. DaSilva L, Howard OM, Rui H, Kirken RA, Farrar WL: Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. *J Biol Chem* 1994, **269**:18267-18270.
42. Letzelter F, Wang Y, Sebald W: The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain. *Eur J Biochem* 1998, **257**:11-20.
43. Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE, et al.: Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. *Science* 1993, **262**:1880-1883.
44. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K: Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. *Science* 1993, **262**:1874-1877.
45. Leonard WJ, Noguchi M, Russell SM: Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). *Adv Exp Med Biol* 1994, **365**:225-232.

46. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K, Nakamura M, Takeshita T: The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. *Annu Rev Immunol* 1996, 14:179-205.
47. Kammer W, Lischke A, Moriggl R, Groner B, Ziemiecki A, Gurniak CB, Berg LJ, Friedrich K: Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling. *J Biol Chem* 1996, 271:23634-23637.
48. Lai SY, Molden J, Liu KD, Puck JM, White MD, Goldsmith MA: Interleukin-4-specific signal transduction events are driven by homotypic interactions of the interleukin-4 receptor alpha subunit. *Embo J* 1996, 15:4506-4514.
49. Fujiwara H, Hanessian SH, Tsutsyko A, Geha RS: Homodimerization of the human interleukin 4 receptor alpha chain induces Cepsilon germline transcripts in B cells in the absence of the interleukin 2 receptor gamma chain. *Proc Natl Acad Sci U S A* 1997, 94:5866-5871.
50. Reichel M, Nelson BH, Greenberg PD, Rothman PB: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. *J Immunol* 1997, 158:5860-5867.
51. Dawson CH, Brown BL, Dobson PR: A 70-kDa protein facilitates interleukin-4 signal transduction in the absence of the common gamma receptor chain. *Biochem Biophys Res Commun* 1997, 233:279-282.
52. Obiri NI, Debinski W, Leonard WJ, Puri RK: Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. *J Biol Chem* 1995, 270:8797-8804.
53. Duschl A, Sebald W: Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond. *Eur Cytokine Netw* 1996, 7:37-49.
54. Schnarr B: Molekulare Mechanismen der Signalübertragung durch den Interleukin-4 Rezeptorkomplex [Dissertation]. Würzburg: Bayerische Julius-Maximilians-Universität: 1997.
55. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA: Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. *Proc Natl Acad Sci U S A* 1996, 93:497-501.
56. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ: cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. *J Biol Chem* 1996, 271:29265-29270.
57. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P: Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. *J Biol Chem* 1996, 271:16921-16926.
58. Fanslow WC, Spriggs MK, Rauch CT, Clifford KN, Macduff BM, Ziegler SF, Schooley KA, Mohler KM, March CJ, Armitage RJ: Identification of a distinct low-affinity receptor for human interleukin-4 on pre-B cells. *Blood* 1993, 81:2998-3005.

59. Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vita N, Ferrara P: **Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex.** *FEBS Lett* 1997, **401**:163-166.
60. Zurawski SM, Chomarat P, Djossou O, Bidaud C, McKenzie AN, Miossec P, Banchereau J, Zurawski G: **The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor.** *J Biol Chem* 1995, **270**:13869-13878.
61. Murata T, Taguchi J, Puri RK: **Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors.** *Blood* 1998, **91**:3884-3891.
62. Hoffman RC, Schalk-Hihi C, Castner BJ, Gibson MG, Rasmussen BD, Zdanov A, Gustchina A, March CJ, Wlodawer A: **Stoichiometry of the complex of human interleukin-4 with its receptor.** *FEBS Lett* 1994, **347**:17-21.
63. Kruse N, Tony HP, Sebald W: **Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement.** *Embo J* 1992, **11**:3237-3244.
64. Tony HP, Shen BJ, Reusch P, Sebald W: **Design of human interleukin-4 antagonists inhibiting interleukin-4- dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency.** *Eur J Biochem* 1994, **225**:659-665.
65. Duschl A: **An antagonistic mutant of interleukin-4 fails to recruit gc into the receptor complex. Characterization by specific crosslinking.** *Eur J Biochem* 1995, **228**:305-310.
66. Yin T, Tsang ML, Yang YC: **JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes.** *J Biol Chem* 1994, **269**:26614-26617.
67. Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu ZJ, Oishi I, Silvennoinen O, Witthuhn BA, Ihle JN, et al.: **Functional activation of Jak1 and Jak3 by selective association with IL- 2 receptor subunits.** *Science* 1994, **266**:1045-1047.
68. Murata T, Puri RK: **Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells.** *Cell Immunol* 1997, **175**:33-40.
69. Izuhara K, Feldman RA, Greer P, Harada N: **Interaction of the c-fes proto-oncogene product with the interleukin-4 receptor.** *J Biol Chem* 1994, **269**:18623-18629.
70. Crowley MT, Harmer SL, DeFranco AL: **Activation-induced association of a 145-kDa tyrosine-phosphorylated protein with Shc and Syk in B lymphocytes and macrophages.** *J Biol Chem* 1996, **271**:1145-1152.
71. Wang J, Hargrove ME, Ting CC: **IL-2 and IL-4 mediate through two distinct kinase pathways for the activation of alphaCD3-induced activated killer cells.** *Cell Immunol* 1996, **174**:138-146.
72. Ikizawa K, Kajiwara K, Koshio T, Yanagihara Y: **Possible role of tyrosine kinase activity in interleukin 4-induced expression of germ-line C epsilon transcripts in a human Burkitt lymphoma B-cell line, DND39.** *J Allergy Clin Immunol* 1994, **94**:620-624.
73. Imani F, Rager KJ, Catipovic B, Marsh DG: **Interleukin-4 (IL-4) induces phosphatidylinositol 3-kinase (p85) dephosphorylation. Implications for the role of SHP-1 in the IL-4-induced signals in human B cells.** *J Biol Chem* 1997, **272**:7927-7931.

74. Siepmann K, Wohlleben G, Gray D: CD40-mediated regulation of interleukin-4 signaling pathways in B lymphocytes. *Eur J Immunol* 1996, **26**:1544-1552.
75. Welham MJ, Bone H, Levings M, Learmonth L, Wang LM, Leslie KB, Pierce JH, Schrader JW: Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. *J Biol Chem* 1997, **272**:1377-1381.
76. Rolling C, Treton D, Pellegrini S, Galanaud P, Richard Y: IL4 and IL13 receptors share the gc chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. *FEBS Lett* 1996, **393**:53-56.
77. Hou J, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL: An interleukin-4-induced transcription factor: IL-4 Stat. *Science* 1994, **265**:1701-1706.
78. Wang LM, Keegan AD, Paul WE, Heidaran MA, Gutkind JS, Pierce JH: IL-4 activates a distinct signal transduction cascade from IL-3 in factor-dependent myeloid cells. *Embo J* 1992, **11**:4899-4908.
79. Pruitt W, Yuan Y, Rose E, Batzer AG, Harada N, Skolnik EY: Association between GRB2/Sos and insulin receptor substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by interleukin-4: implications for Ras activation by insulin. *Mol Cell Biol* 1995, **15**:1778-1785.
80. Wery S, Letourneur M, Bertoglio J, Pierre J: Interleukin-4 induces activation of mitogen-activated protein kinase and phosphorylation of shc in human keratinocytes. *J Biol Chem* 1996, **271**:8529-8532.
81. Chuang LM, Tai TY, Kahn RC, Wu HP, Lee SC, Lin BJ: Signal transduction pathways for interleukin 4 and insulin in human hepatoma cells. *J Biochem (Tokyo)* 1996, **120**:111-116.
82. Nelms K, Snow AL, Hu-Li J, Paul WE: FRIP, a hematopoietic cell-specific rasGAP-interacting protein phosphorylated in response to cytokine stimulation. *Immunity* 1998, **9**:13-24.
83. Izuhara K, Harada N: Interleukin-4 (IL-4) induces protein tyrosine phosphorylation of the IL-4 receptor and association of phosphatidylinositol 3-kinase to the IL-4 receptor in a mouse T cell line, HT2. *J Biol Chem* 1993, **268**:13097-13102.
84. Losman JA, Chen XP, Hilton D, Rothman P: Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. *J Immunol* 1999, **162**:3770-3774.
85. Naka T, Narasaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al.: Structure and function of a new STAT-induced STAT inhibitor. *Nature* 1997, **387**:924-929.
86. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al.: A new protein containing an SH2 domain that inhibits JAK kinases. *Nature* 1997, **387**:921-924.
87. Keegan AD, Pierce JH: The interleukin-4 receptor: signal transduction by a hematopoietin receptor. *J Leukoc Biol* 1994, **55**:272-279.

88. Gustafson TA, He W, Craparo A, Schaub CD, O'Neill TJ: **Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non- SH2 domain.** *Mol Cell Biol* 1995, **15**:2500-2508.
89. Zhou MM, Huang B, Olejniczak ET, Meadows RP, Shuker SB, Miyazaki M, Trub T, Shoelson SE, Fesik SW: **Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain.** *Nat Struct Biol* 1996, **3**:388-393.
90. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG, Jr., Glasheen E, Lane WS, Pierce JH, White MF: **Role of IRS-2 in insulin and cytokine signalling.** *Nature* 1995, **377**:173-177.
91. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, et al.: **Disruption of IRS-2 causes type 2 diabetes in mice.** *Nature* 1998, **391**:900-904.
92. Sun XJ, Crimmins DL, Myers MG, Jr., Miralpeix M, White MF: **Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1.** *Mol Cell Biol* 1993, **13**:7418-7428.
93. Lefort S, Vita N, Reeb R, Caput D, Ferrara P: **IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells.** *FEBS Lett* 1995, **366**:122-126.
94. Welham MJ, Learmonth L, Bone H, Schrader JW: **Interleukin-13 signal transduction in lymphohemopoietic cells. Similarities and differences in signal transduction with interleukin-4 and insulin.** *J Biol Chem* 1995, **270**:12286-12296.
95. Susa M, Rohner D, Bichsel S: **Differences in binding of PI 3-kinase to the src-homology domains 2 and 3 of p56 lck and p59 fyn tyrosine kinases.** *Biochem Biophys Res Commun* 1996, **220**:729-734.
96. Zamorano J, Wang HY, Wang LM, Pierce JH, Keegan AD: **IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway.** *J Immunol* 1996, **157**:4926-4934.
97. Welham MJ, Duronio V, Leslie KB, Bowtell D, Schrader JW: **Multiple hemopoietins, with the exception of interleukin-4, induce modification of Shc and mSos1, but not their translocation.** *J Biol Chem* 1994, **269**:21165-21176.
98. Welham MJ, Duronio V, Schrader JW: **Interleukin-4-dependent proliferation dissociates p44erk-1, p42erk-2, and p21ras activation from cell growth.** *J Biol Chem* 1994, **269**:5865-5873.
99. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O: **Signaling through the hematopoietic cytokine receptors.** *Annu Rev Immunol* 1995, **13**:369-398.
100. Bennett BL, Cruz R, Lacson RG, Manning AM: **Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E- selectin gene transcription is mediated by STAT6 antagonism of NF- kappaB.** *J Biol Chem* 1997, **272**:10212-10219.
101. Ohmori Y, Hamilton TA: **IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages.** *J Immunol* 1997, **159**:5474-5482.
102. Darnell JE, Jr.: **STATs and gene regulation.** *Science* 1997, **277**:1630-1635.
103. Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL: **Components of a Stat recognition code: evidence for two layers of molecular selectivity.** *Immunity* 1995, **2**:689-697.

104. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T: SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. *Science* 1991, **252**:668-674.
105. Mikita T, Campbell D, Wu P, Williamson K, Schindler U: Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. *Mol Cell Biol* 1996, **16**:5811-5820.
106. Ihle JN: STATs: signal transducers and activators of transcription. *Cell* 1996, **84**:331-334.
107. Wen Z, Zhong Z, Darnell JE, Jr.: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. *Cell* 1995, **82**:241-250.
108. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, et al.: A family of cytokine-inducible inhibitors of signalling. *Nature* 1997, **387**:917-921.
109. Heim MH: The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. *J Recept Signal Transduct Res* 1999, **19**:75-120.
110. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A: Antennapedia homeobox peptide regulates neural morphogenesis. *Proc Natl Acad Sci U S A* 1991, **88**:1864-1868.
111. Joliot AH, Triller A, Volovitch M, Pernelle C, Prochiantz A:  $\alpha$ -2,8-Polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide. *New Biol* 1991, **3**:1121-1134.
112. Krumlauf R: Hox genes in vertebrate development. *Cell* 1994, **78**:191-201.
113. Gehring WJ, Affolter M, Bürglin T: Homeodomain proteins. *Annu Rev Biochem* 1994, **63**:487-526.
114. Derossi D, Joliot AH, Chassaing G, Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. *J Biol Chem* 1994, **269**:10444-10450.
115. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A: Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. *J Biol Chem* 1996, **271**:18188-18193.
116. Prochiantz A: Getting hydrophilic compounds into cells: lessons from homeopeptides. *Curr Opin Neurobiol* 1996, **6**:629-634.
117. Berlose JP, Convert O, Derossi D, Brunissen A, Chassaing G: Conformational and associative behaviours of the third helix of antennapedia homeodomain in membrane-mimetic environments. *Eur J Biochem* 1996, **242**:372-386.
118. Chatelin L, Volovitch M, Joliot AH, Perez F, Prochiantz A: Transcription factor hoxa-5 is taken up by cells in culture and conveyed to their nuclei. *Mech Dev* 1996, **55**:111-117.
119. Finkelman FD, Katona IM, Urban JF, Jr., Holmes J, Ohara J, Tung AS, Sample JV, Paul WE: IL-4 is required to generate and sustain in vivo IgE responses. *J Immunol* 1988, **141**:2335-2341.
120. Grunewald SM, Werthmann A, Schnarr B, Klein CE, Bröcker EB, Mohrs M, Brombacher F, Sebal W, Duschl A: An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune

- response to allergen and development of allergic symptoms in vivo. *J Immunol* 1998, **160**:4004-4009.
121. Maliszewski CR, Sato TA, Davison B, Jacobs CA, Finkelman FD, Fanslow WC: In vivo biological effects of recombinant soluble interleukin-4 receptor. *Proc Soc Exp Biol Med* 1994, **206**:233-237.
122. Renz H, Enssle K, Lauffer L, Kurrale R, Gelfand EW: Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. *Int Arch Allergy Immunol* 1995, **106**:46-54.
123. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L: Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 1999, **160**:1816-1823.
124. Eck MJ, Dhe-Paganon S, Trub T, Nolte RT, Shoelson SE: Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. *Cell* 1996, **85**:695-705.
125. Pawson T, Gish GD: SH2 and SH3 domains: from structure to function. *Cell* 1992, **71**:359-362.
126. Mikita T, Daniel C, Wu P, Schindler U: Mutational analysis of the STAT6 SH2 domain. *J Biol Chem* 1998, **273**:17634-17642.
127. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, et al.: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. *Nature* 1996, **380**:630-633.
128. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S: Essential role of Stat6 in IL-4 signalling. *Nature* 1996, **380**:627-630.
129. Kaplan MH, Schindler U, Smiley ST, Grusby MJ: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. *Immunity* 1996, **4**:313-319.
130. Kruse N, Lehrnbecher T, Sebald W: Site-directed mutagenesis reveals the importance of disulfide bridges and aromatic residues for structure and proliferative activity of human interleukin-4. *FEBS Lett* 1991, **286**:58-60.
131. Weigel U, Meyer M, Sebald W: Mutant proteins of human interleukin 2. Renaturation yield, proliferative activity and receptor binding. *Eur J Biochem* 1989, **180**:295-300.
132. Grunewald SM, Kunzmann S, Schnarr B, Ezernieks J, Sebald W, Duschl A: A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction. *J Biol Chem* 1997, **272**:1480-1483.
133. Solari R, Quint D, Obrey H, McNamee A, Bolton E, Hissey P, Champion B, Zanders E, Chaplin A, Coomber B, et al.: Purification and characterization of recombinant human interleukin 4. Biological activities, receptor binding and the generation of monoclonal antibodies. *Biochem J* 1989, **262**:897-908.
134. Yokota T, Otsuka T, Mosmann T, Banchereau J, DeFrance T, Blanchard D, De Vries JE, Lee F, Arai K: Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. *Proc Natl Acad Sci U S A* 1986, **83**:5894-5898.

135. Théodore L, Derossi D, Chassaing G, Llirbat B, Kubes M, Jordan P, Chneiweiss H, Godement P, Prochiantz A: **Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse.** *J Neurosci* 1995, **15**:7158-7167.
136. Hall H, Williams EJ, Moore SE, Walsh FS, Prochiantz A, Doherty P: **Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide.** *Curr Biol* 1996, **6**:580-587.
137. Derossi D, Williams EJ, Green PJ, Duncan DJ, Doherty P: **Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide.** *Biochem Biophys Res Commun* 1998, **251**:148-152.
138. Chait BT, Kent SB: **Weighing naked proteins: practical, high-accuracy mass measurement of peptides and proteins.** *Science* 1992, **257**:1885-1894.
139. Gill SC, von Hippel PH: **Calculation of protein extinction coefficients from amino acid sequence data.** *Anal Biochem* 1989, **182**:319-326.
140. Bradford MM: **A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.** *Anal Biochem* 1976, **72**:248-254.
141. Laemmli UK: **Cleavage of structural proteins during the assembly of the head of bacteriophage T4.** *Nature* 1970, **227**:680-685.
142. Schägger H, von Jagow G: **Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.** *Anal Biochem* 1987, **166**:368-379.
143. Swank RT, Munkres KD: **Molecular weight analysis of oligopeptides by electrophoresis in polyacrylamide gel with sodium dodecyl sulfate.** *Anal Biochem* 1971, **39**:462-477.
144. Cabrillat H, Galizzi JP, Djossou O, Arai N, Yokota T, Arai K, Banchereau J: **High affinity binding of human interleukin 4 to cell lines.** *Biochem Biophys Res Commun* 1987, **149**:995-1001.
145. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K: **Cloning of the gamma chain of the human IL-2 receptor.** *Science* 1992, **257**:379-382.
146. Gershoni JM, Palade GE: **Protein blotting: principles and applications.** *Anal Biochem* 1983, **131**:1-15.
147. Simm A, Hoppe V, Tatje D, Schenzinger A, Hoppe J: **PDGF-AA effectively stimulates early events but has no mitogenic activity in AKR-2B mouse fibroblasts.** *Exp Cell Res* 1992, **201**:192-199.
148. Troy CM, Derossi D, Prochiantz A, Greene LA, Shelanski ML: **Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway.** *J Neurosci* 1996, **16**:253-261.
149. Garbay-Jaureguiberry C, Ficheux D, Roques BP: **Solid phase synthesis of peptides containing the non-hydrolysable analog of (O)phosphotyrosine, p(CH<sub>2</sub>PO<sub>3</sub>H<sub>2</sub>)Phe.** Application to

- the synthesis of 344-357 sequences of the beta 2 adrenergic receptor. *Int J Pept Protein Res* 1992, **39**:523-527.
150. Imbert V, Peyron JF, Farahi Far D, Mari B, Auburger P, Rossi B: Induction of tyrosine phosphorylation and T-cell activation by vanadate peroxide, an inhibitor of protein tyrosine phosphatases. *Biochem J* 1994, **297**:163-173.
151. Fenteany G, Schreiber SL: Lactacystin, proteasome function, and cell fate. *J Biol Chem* 1998, **273**:8545-8548.
152. Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN: Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. *Immunity* 1999, **11**:225-230.
153. Lischke A, Kammer W, Friedrich K: Different human interleukin-4 mutants preferentially activate human or murine common receptor gamma chain. *Eur J Biochem* 1995, **234**:100-107.
154. Bömmel H, Li-Weber M, Serfling E, Duschl A: The environmental pollutant pyrene induces the production of IL-4. *J Allergy Clin Immunol* 2000, **105**:796-802.
155. Goodman PA, Niehoff LB, Uckun FM: Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells. *J Biol Chem* 1998, **273**:17742-17748.
156. Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. *Annu Rev Cell Dev Biol* 1997, **13**:513-609.
157. Brown MT, Cooper JA: Regulation, substrates and functions of src. *Biochim Biophys Acta* 1996, **1287**:121-149.
158. Smerz-Bertling C, Duschl A: Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor. *J Biol Chem* 1995, **270**:966-970.
159. Schnarr B, Ezernieks J, Sebald W, Duschl A: IL-4 receptor complexes containing or lacking the gc chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins. *Int Immunol* 1997, **9**:861-868.
160. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T, Paul WE: Identification of a T cell-derived b cell growth factor distinct from interleukin 2. *J Exp Med* 1982, **155**:914-923.
161. Brown MA, Pierce JH, Watson CJ, Falco J, Ihle JN, Paul WE: B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. *Cell* 1987, **50**:809-818.
162. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE: Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. *Nature* 1989, **339**:64-67.
163. Coffman RL, Lebman DA, Rothman P: Mechanism and regulation of immunoglobulin isotype switching. *Adv Immunol* 1993, **54**:229-270.
164. Renz H: The central role of T-cells in allergic sensitization and IgE regulation. *Exp Dermatol* 1995, **4**:173-182.

165. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC: **Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma.** *Lancet* 1998, **352**:1109-1113.
166. Schindler C, Darnell JE, Jr.: **Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.** *Annu Rev Biochem* 1995, **64**:621-651.
167. Quelle FW, Shimoda K, Thierfelder W, Fischer C, Kim A, Ruben SM, Cleveland JL, Pierce JH, Keegan AD, Nelms K, et al.: **Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis.** *Mol Cell Biol* 1995, **15**:3336-3343.
168. Ryan JJ, McReynolds LJ, Keegan A, Wang LH, Garfein E, Rothman P, Nelms K, Paul WE: **Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor.** *Immunity* 1996, **4**:123-132.
169. Kopf M, Brombacher F, Kohler G, Kienzle G, Widmann KH, Lefrang K, Humborg C, Ledermann B, Solbach W: **IL-4-deficient Balb/c mice resist infection with Leishmania major.** *J Exp Med* 1996, **184**:1127-1136.
170. Pearce EJ, Cheever A, Leonard S, Covalesky M, Fernandez-Botran R, Kohler G, Kopf M: **Schistosoma mansoni in IL-4-deficient mice.** *Int Immunol* 1996, **8**:435-444.
171. Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, Brombacher F: **Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling.** *J Immunol* 1999, **162**:7302-7308.
172. Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T, et al.: **Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav.** *Mol Cell Biol* 1994, **14**:2777-2785.
173. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, et al.: **SH2 domains recognize specific phosphopeptide sequences.** *Cell* 1993, **72**:767-778.
174. Brugge JS: **New intracellular targets for therapeutic drug design.** *Science* 1993, **260**:918-919.
175. Waksman G, Kominos D, Robertson SC, Pant N, Baltimore D, Birge RB, Cowburn D, Hanafusa H, Mayer BJ, Overduin M, et al.: **Crystal structure of the phosphotyrosine recognition domain SH2 of v- src complexed with tyrosine-phosphorylated peptides [see comments].** *Nature* 1992, **358**:646-653.
176. Overduin M, Rios CB, Mayer BJ, Baltimore D, Cowburn D: **Three-dimensional solution structure of the src homology 2 domain of c- abl.** *Cell* 1992, **70**:697-704.
177. Rahuel J, Gay B, Erdmann D, Strauss A, Garcia-Echeverria C, Furet P, Caravatti G, Fretz H, Schoepfer J, Grutter MG: **Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode.** *Nat Struct Biol* 1996, **3**:586-589.
178. Lee CH, Kominos D, Jacques S, Margolis B, Schlessinger J, Shoelson SE, Kuriyan J: **Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase.** *Structure* 1994, **2**:423-438.

179. Pascal SM, Singer AU, Gish G, Yamazaki T, Shoelson SE, Pawson T, Kay LE, Forman-Kay JD: Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-gamma 1 complexed with a high affinity binding peptide. *Cell* 1994, 77:461-472.
180. Eck MJ, Shoelson SE, Harrison SC: Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. *Nature* 1993, 362:87-91.
181. Narula SS, Yuan RW, Adams SE, Green OM, Green J, Philips TB, Zydowsky LD, Botfield MC, Hatada M, Laird ER, et al.: Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide. *Structure* 1995, 3:1061-1073.
182. Hatada MH, Lu X, Laird ER, Green J, Morgenstern JP, Lou M, Marr CS, Phillips TB, Ram MK, Theriault K, et al.: Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. *Nature* 1995, 377:32-38.
183. Sawyer TK: Src homology-2 domains: structure, mechanisms, and drug discovery. *Biopolymers* 1998, 47:243-261.
184. Cussac D, Vidal M, Leprince C, Liu WQ, Cornille F, Tiraboschi G, Roques BP, Garbay C: A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. *Faseb J* 1999, 13:31-38.
185. Williams EJ, Duncan DJ, Green PJ, Howell FV, Derossi D, Walsh FS, Doherty P: Selective inhibition of growth factor-stimulated mitogenesis by a cell- permeable Grb2-binding peptide. *J Biol Chem* 1997, 272:22349-22354.
186. Peck D, Isacke CM: Hyaluronan-dependent cell migration can be blocked by a CD44 cytoplasmic domain peptide containing a phosphoserine at position 325. *J Cell Sci* 1998, 111:1595-1601.
187. Bonfanti M, Taverna S, Salmoda M, M Di, Broggini M: p21waf1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. *Cancer Res* 1997, 57:1442-1446.
188. Troy CM, Stefanis L, Prochiantz A, Greene LA, Shelanski ML: The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. *Proc Natl Acad Sci U S A* 1996, 93:5635-5640.
189. Foster PS: STAT6: an intracellular target for the inhibition of allergic disease. *Clin Exp Allergy* 1999, 29:12-16.
190. Vivès E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J Biol Chem* 1997, 272:16010-16017.
191. Schwarze SR, Dowdy SF: In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. *Trends Pharmacol Sci* 2000, 21:45-48.
192. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. *Nat Med* 1998, 4:1449-1452.

193. Mann DA, Frankel AD: Endocytosis and targeting of exogenous HIV-1 Tat protein. *Embo J* 1991, **10**:1733-1739.
194. Pooga M, Hallbrink M, Zorko M, Langel U: Cell penetration by transportan. *Faseb J* 1998, **12**:67-77.
195. Zorko M, Pooga M, Saar K, Rezaei K, Langel U: Differential regulation of GTPase activity by mastoparan and galparan. *Arch Biochem Biophys* 1998, **349**:321-328.
196. Pooga M, Lindgren M, Hallbrink M, Brakenhielm E, Langel U: Galanin-based peptides, galparan and transportan, with receptor- dependent and independent activities. *Ann N Y Acad Sci* 1998, **863**:450-453.
197. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, Melzig M, Bienert M: Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non- endocytically. *Biochim Biophys Acta* 1998, **1414**:127-139.
198. Scheller A, Oehlke J, Wiesner B, Dathe M, Krause E, Beyermann M, Melzig M, Bienert M: Structural requirements for cellular uptake of alpha-helical amphipathic peptides. *J Pept Sci* 1999, **5**:185-194.
199. Perlmutter RM, Levin SD, Appleby MW, Anderson SJ, Alberola-Illa J: Regulation of lymphocyte function by protein phosphorylation. *Annu Rev Immunol* 1993, **11**:451-499.
200. Molina TJ, Kishihara K, Siderovski DP, van Ewijk W, Narendran A, Timms E, Wakeham A, Paige CJ, Hartmann KU, Veillette A, et al.: Profound block in thymocyte development in mice lacking p56<sup>lck</sup>. *Nature* 1992, **357**:161-164.
201. Straus DB, Weiss A: Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. *Cell* 1992, **70**:585-593.
202. Miyazaki T, Taniguchi T: Coupling of the IL2 receptor complex with non-receptor protein tyrosine kinases. *Cancer Surv* 1996, **27**:25-40.
203. Kobayashi N, Kono T, Hatakeyama M, Minami Y, Miyazaki T, Perlmutter RM, Taniguchi T: Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/56lyn with the interleukin 2 receptor: implications for redundancy and pleiotropism in cytokine signal transduction. *Proc Natl Acad Sci U S A* 1993, **90**:4201-4205.
204. Tsygankov AY, Spana C, Rowley RB, Penhallow RC, Burkhardt AL, Bolen JB: Activation-dependent tyrosine phosphorylation of Fyn-associated proteins in T lymphocytes. *J Biol Chem* 1994, **269**:7792-7800.
205. Wang HY, Paul WE, Keegan AD: IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. *Immunity* 1996, **4**:113-121.
206. Park LS, Friend D, Sassenfeld HM, Urdal DL: Characterization of the human B cell stimulatory factor 1 receptor. *J Exp Med* 1987, **166**:476-488.
207. Obiri NI, Leland P, Murata T, Debinski W, Puri RK: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. *J Immunol* 1997, **158**:756-764.

208. He YW, Malek TR: **The IL-2 receptor gamma c chain does not function as a subunit shared by the IL-4 and IL-13 receptors. Implication for the structure of the IL-4 receptor.** *J Immunol* 1995, **155**:9-12.
209. McKenzie AN, Culpepper JA, de Waal Malefy R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S, et al.: **Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function.** *Proc Natl Acad Sci U S A* 1993, **90**:3735-3739.
210. de Waal Malefy R, Abrams JS, Zurawski SM, Lecron JC, Mohan-Peterson S, Sanjanwala B, Bennett B, Silver J, de Vries JE, Yssel H: **Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells.** *Int Immunol* 1995, **7**:1405-1416.
211. Zurawski SM, Vega F, Jr., Huyghe B, Zurawski G: **Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction.** *Embo J* 1993, **12**:2663-2670.
212. Duschl A, Müller T, Sebald W: **Antagonistic mutant proteins of interleukin-4.** *Behring Inst Mitt* 1995,:87-94.
213. Foxwell BM, Woerly G, Ryffel B: **Identification of interleukin 4 receptor-associated proteins and expression of both high- and low-affinity binding on human lymphoid cells.** *Eur J Immunol* 1989, **19**:1637-1641.
214. Galizzi JP, Castle B, Djossou O, Harada N, Cabrillat H, Yahia SA, Barrett R, Howard M, Banchereau J: **Purification of a 130-kDa T cell glycoprotein that binds human interleukin 4 with high affinity.** *J Biol Chem* 1990, **265**:439-444.